Connect with us

Fertility

Interview: Bloom Diagnostics’ Dr Angelica Kohlmann

Published

on

As a new home fertility test is approved, Femtech World finds out how digital technology could transform healthcare around the world.

Dr Angelica Kohlmann joins our call from Austria. As the executive chairman of the Swiss company Bloom Diagnostics, she is happy to announce its new at-home Ovarian Reserve test that measures the AMH (anti-Müllerian hormone) level and gives patients encrypted results on an app.

Her aim is to make fertility tests accessible to everyone using a cheaper and less invasive procedure and the AMH test marks a major step towards a digitalisation of the medical world.

“This is the future,” Angelica says. “We will have a healthcare system where if you don’t feel well in the morning, you open an app that will register your symptoms and guide you from there,” she says.

“You will receive an e-prescription and have your medication delivered to your door. This way you will be fully taken care of from home without the risk of being infected in a hospital.”

The pandemic has accelerated the transition towards digital technology within the NHS in order to free up space, enable remote working and reduce the risk of infection transmission. According to a recent report, there has also been a surge in patients’ uptake of remote health services, including registrations for the NHS app and e-prescription services.

Angelica describes Bloom’s test as a huge development. “We decided to develop a home test because until today, the only way to have it done was by going to a gynaecologist and we thought that was obsolete,” she explains.

“So, we digitised, so to say, the drop of blood. We allow women to take the test multiple times a year and we created the first global AMH test that gives feedback in real time. It was a challenge in the beginning, because AMH has very low concentrations in your blood, meaning that detection is not that easy with rapid tests. But we solved the problem successfully and we’re now registered in Germany, Austria, Switzerland and Italy and very soon in the UK.”

Delays in fertility tests, treatment and counselling during the pandemic meant that medical firms had to rethink their approach and adapt to the current challenges. Therefore, developing an app that could deliver immediate results was a key step, says Angelica.

“We knew that only a super easy to use product would work. Today, people want things right here, right now so why have a screen reader in a lab,” she continues. “An app can tell you much more and if something is wrong, we send people to the doctor.”

Indeed, research shows that in the past two years more and more people have become familiar with the idea of tracking their health by using an app. Downloads increased by nearly 200 per cent from summer 2019 to summer 2020 and continue to grow.

However, there are still people who are sceptical about these developments and health tech companies are very aware of that.

Angelica believes “there is still a lot of scepticism in society, so building trust is definitely something that we really need to work on”.

She adds: “We’re also trying to increase the reach ability via partnerships with clinics and insurance companies who want to really go into prevention regarding any disease.”

As our society evolves, our healthcare requirements naturally evolve. We will have a completely different level of healthcare, Angelica agrees. However, ensuring that everyone has access to a state-of-the-art medical system will be crucial.

“We need to make sure that we reach those in unaccessible regions, living in remote places in Africa and in other developing countries. Only this way our developments will come to the benefit of thousands of women in need.”

 

 

Sorina Mihaila is the Femtech World editor, covering technology, research and innovation in women's health and wellbeing.

Fertility

Maven Clinic launches programme for couples struggling to conceive

The programme aims to address the gap between trying to conceive and fertility treatment

Published

on

The US virtual clinic Maven has launched a health coaching programme in an effort to expand family-building options for couples struggling to conceive.

With 86 per cent of women not receiving preconception care from their family physician or OB/GYN, Maven’s Trying-To-Conceive (TTC) health coaching programme aims to support people who may be struggling and want to get pregnant without IVF.

The programme includes one-to-one support, reproductive education, ovulation tracking kits, as well as referrals to resources for mental health and nutrition.

“Maven is making sure every family can access the shortest pathway to having a healthy baby,” said Kate Ryder, Maven Clinic founder and CEO.

“We have constructed a unique model that, for the first time, aligns incentives among the stakeholders in healthcare to support people who are trying to conceive.”

To address the gap between trying to conceive and fertility treatment, Maven’s TTC Coaching service brings the benefits of health coaching to fertility care, providing members with “personalised” support and reproductive education, Ryder said. 

Dr Neel Shah, Maven Clinic’s chief medical officer, added: “While most sex education is spent teaching people how to avoid pregnancy, very little time is invested in empowering them with the guidance needed to become pregnant when they’re ready.

“Our coaching program supports couples to understand why they are struggling to conceive and in many cases helps them get pregnant without needing IVF.”

Further product enhancements the Maven team has announced include the Maven Managed Benefit platform, as well as an expansion of the company’s reproductive urology provider network for male fertility support.

To receive the Femtech World newsletter, sign up here.

Continue Reading

Fertility

Brazilian fertility network FertGroup partners with Future Fertility to launch innovative oocyte assessment software across all clinics

The collaboration marks a significant milestone in advancing fertility care in Brazil

Published

on

FertGroup Medicina Reproductiva, a dynamic network of fertility clinics in Brazil, is proud to announce its partnership with Future Fertility to introduce cutting-edge oocyte assessment software, VIOLET™ and MAGENTA™, across its expanding network of clinics.

With nine clinics currently under FertGroup ownership, the network is poised for significant growth, aiming to surpass 15 clinics within the coming year.

This expansion is a response to the escalating demand for fertility services in Brazil, a market that has seen remarkable growth (17.6 per cent CAGR compared to the global average of ~10 per cent).

Factors driving this growth include an underserved market, rising medical tourism, and evolving population dynamics emphasising the need for advanced fertility solutions.

Led by private equity investors XP Private Equity fund, FertGroup is committed to revolutionising the fertility care landscape in Brazil and beyond.

Future Fertility is the first and only AI company to offer a comprehensive and easily integratable solution to oocyte assessment for clinics around the world.

With the world’s largest oocyte dataset, the use of this software (VIOLET™ and MAGENTA™) is at the forefront of this partnership, enabling clinicians, embryologists and patients to gain broad access to AI-driven insights about oocyte quality.

Nelson Guerreiro Pestana, CEO of FertGroup Medicina Reproductiva, highlighted the importance of integrating such innovative technologies: “At FertGroup, we are committed to bringing forward medical innovation that directly benefits the lives of Brazilians.

“Partnering with Future Fertility reinforces our market-leading position and reputation for excellence in fertility care.”

This technology optimises decisions regarding oocyte cryopreservation, ICSI IVF treatment approaches and oocyte donation. It also empowers patients by offering valuable insights into how their health status impacts expected fertility outcomes, helping clinics differentiate their service offering and provide a more patient-centric approach to fertility care.

Christy Prada, CEO of Future Fertility, expressed excitement about the expansion into the Brazilian market: “We are thrilled to partner with FertGroup Medicina Reproductiva in introducing Future Fertility’s innovative oocyte assessment software to Brazil.

“FertGroup is leading the market as the first network in Brazil to implement this technology, marking a significant step forward for fertility care in the region.”

Dr Edson Borges Jr, chief medical officer of FertGroup Medicina Reproductiva, emphasised the significance of oocyte quality in care delivery: “As a scientific leader in the field, we believe in bringing cutting edge technology to our patients, and supporting further research into new approaches to measuring and assessing progress in fertility treatment.

“Oocyte quality is a critical aspect of fertility care, and we believe that by integrating Future Fertility’s advanced tools into our care models we will advance the science in this space and demonstrate the value of leveraging oocyte quality in decision making.”

“Integrating the Future Fertility technology into our labs has been completely seamless” remarked Maria Cecilia Cardoso, group lab director.

“We already can see the value of the workflow integration, and this was a major decision factor for us. We are excited to see the benefits this will bring to decision making, providing an objective and personalised view of quality control into the process.”

This collaboration between FertGroup Medicina Reproductiva and Future Fertility marks a significant milestone in advancing fertility care in Brazil.

The introduction of VIOLET™ and MAGENTA™ software underscores FertGroup’s dedication to innovation and patient-centric care, solidifying its position as a pioneer in the Brazilian fertility market.

Continue Reading

News

Don’t politicise fertility, leaders warn after MP’s ‘patronising’ intervention

It is worrying to see a “deeply personal” women’s health issue being debated by politicians, fertility benefits providers told Femtech World

Published

on

UK femtech leaders have warned of the dangers of playing politics with fertility services following what they call “unhelpful, patronising and disrespectful” comments from an MP. 

The Conservative MP Miriam Cates raised concerns this week that women are being exploited into freezing their eggs, claiming that “most hopeful mothers are sold a lie”.

She said she fears women are being given “false promises” by large corporations offering them money to freeze their eggs to put off having children to a later age.

However, reproductive benefits providers labelled the comments as “unhelpful, patronising and disrespectful”.

Eileen Burbidge MBE, executive director at reproductive health start-up Fertifa, said: “Policymakers should absolutely be giving more attention to protecting reproductive health access and treatment options for women, given how shamefully ignored women’s health has been for too long.

“However, characterising egg freezing in the way that Miriam Cates has recently done is unhelpful, patronising and disrespectful to women who rely upon the option to freeze their eggs whether for medical reasons, to donate to others who suffer from infertility or for their own future optionality to relieve patriarchal societal pressures of finding a life partner or starting a family.”

Far from being exploitative, employers who offer financial and wellbeing access to reproductive healthcare are responding to what their talent is asking for, Burbidge, who served on former British prime minister David Cameron’s Business Advisory Group, told Femtech World.

“Data has consistently shown that women do not choose to freeze their eggs in order to work longer or prioritise their careers, but rather because they’ve yet to find a life partner and wish to not succumb to patriarchal societal pressures to do so.

“The fact that companies are supporting this will hopefully mean more women recognise the fact that the likelihood of success increases the earlier they freeze their eggs.”

Leila Thabet, UK general manager at Maven Clinic, said it is concerning to see a highly emotionally charged women’s health issue being debated by politicians and commentators with their own agendas.

“It is correct that egg freezing will not work for all women, but rather than paint an entirely bleak picture of the practice, it is vital that we empower women with facts around the procedure so they do not fall prey to exploitative clinics and operators who may not have their best interests at heart,” she said.

“At a time when data shows that women’s health care needs are still largely being neglected, it is unhelpful to dismiss the provision of women’s and family health benefits in the workplace as exploitative. This is as unhelpful as it is untrue.”

Jenny Saft, co-founder and CEO of fertility benefits provider Apryl, said there is a misconception that fertility benefits platforms offer egg freezing to keep women in the workplace.

“This is not how these programmes are designed or implemented. From my experience, it’s rare to find a company that limits its fertility benefits to egg freezing alone,” she explained.

“Typically, employers provide a comprehensive suite of fertility and family-forming options, including but not limited to egg freezing, sperm freezing, IVF, adoption, and surrogacy.”

Egg freezing has seen a sharp rise in the UK. More women than ever before are undergoing procedures, with egg and embryo freezing now the fastest growing fertility treatments in the country.

According to the Human Fertilisation and Embryology Authority (HEFA), egg freezing and storage saw a 64 per cent increase in 2021 compared to 2019.

The procedure, which is not available on the NHS, is largely carried out by private clinics at a price tag of £7,000 to £8,000. Fertility benefits platforms claim to provide financial and emotional support for egg freezing, giving women more freedom over when to start a family.

“When egg freezing is offered as an employee benefit it takes away the financial burden of egg freezing,” said Dr Catherine Hill, head of policy and public affairs at Fertility Network UK.

“However, it does not remove the health risks and side effects associated with the invasive medical process, or the emotionally demanding and often upsetting nature of freezing your eggs – all of which women need to consider before making any decision.

“Because this is such a big life choice, it is vital women do not feel under any obligation from their employer to take advantage of this employee benefit.”

Although the procedure enables some women to delay motherhood until the time that is right for them, egg freezing should never be seen as a fertility insurance policy, Hill said.

She added: “Making a decision on the right time to approach parenthood or to attempt to postpone it is a very individual commitment and must be made without pressure from anyone else, including employers. Egg freezing should be about widening women’s reproductive choices on when to have a baby, not enabling a scenario where women feel forced to delay motherhood.”

Becky Kearns, co-founder of Fertility Matters at Work, said it is crucial that companies educate employees and empower them to make informed choices.

“While egg freezing will be seen as a huge benefit and attraction for the next generation of workforce, it needs to be balanced with information and facts to allow people to make informed choices,” she told Femtech World.

“Organisations should be supporting fertility treatment as a whole where possible, not just for those early in their careers. If the focus is solely on egg freezing there’s the risk that this may be perceived as a means to encourage employees to delay having a family, to the short-term benefit of the employer.

“This benefit on its own, without balanced information and education about outcomes and overall fertility awareness, may result in people purposely delaying having children, thinking they have a guarantee for when the time is right, when in reality it gives them a chance.

Miriam Cates has been approached for comment.

To receive the Femtech World newsletter, sign up here.

Continue Reading

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.